BlackRock
BlackRock is a global investment management corporation founded in 1988 and headquartered in New York City. It provides a diverse array of services, including investment advisory, risk management, and asset management across various asset classes and sectors, such as real estate, energy, and technology. The firm manages funds for a wide range of clients, including large institutions and individual investors, focusing on delivering tailored investment solutions to help secure better financial futures. BlackRock operates through its subsidiaries, including BlackRock Capital Investment Advisors, which offers investment advisory services, and BlackRock Private Equity Partners, which specializes in direct and fund investments in private equity and venture capital. With a strong emphasis on both public and private markets, BlackRock’s expertise spans multiple strategies and geographic regions, making it one of the world's largest asset managers, with trillions of dollars entrusted to its care.
MNTN is a provider of cloud-based advertising software designed for direct marketers, agencies, and brands of all sizes. Its comprehensive advertising suite enables users to effectively launch retargeting and prospecting campaigns across various platforms, including display, mobile, and social media. Additionally, MNTN offers a creative suite that empowers users to design visually appealing advertisements utilizing available content. The platform is known for its emphasis on transparency and control, allowing advertisers to manage their campaigns efficiently with one of the fastest go-live times in the industry. MNTN has received multiple accolades for its innovative solutions and workplace culture, establishing itself as a prominent player in the digital advertising landscape.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.